TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have schizophrenia~* Female patients of childbearing potential must be using a medically accepted means of contraception~* Patients must have completed (within 10 days) another IM olanzapine depot study if permitted by that study's protocol.~Exclusion Criteria:~* Patients must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry~* Female patients must not be pregnant or breast-feeding~* Patients must not be experiencing acute, serious or unstable medical conditions other than schizophrenia or schizoaffective disorder~* Patients must not have a substance (except nicotine or caffeine) dependence within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Intramuscular Olanzapine Depot (Type: EXPERIMENTAL): Intramuscular (IM) olanzapine depot flexible dosing and flexible interval

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Locally advanced or metastatic breast cancer~* HER2-negative and hormone receptor-positive status (common breast cancer classification tests)~* Postmenopausal woman~* A tumor sample must be shipped to a Novartis designated laboratory for identification of biomarkers (PI3K activation status)~* Progression or recurrence of breast cancer while on or after aromatase inhibitor treatment~* Measurable disease or non measurable disease bone lesions in the absence of measurable disease as per RECIST 1.1~* Adequate bone marrow and organ function defined by laboratory values~Key Exclusion Criteria:~* Previous treatment with PI3K inhibitors, AKT inhibitors, mTOR inhibitor or fulvestrant~* More than one prior chemotherapy line for metastatic disease~* Symptomatic brain metastases~* Increasing or chronic treatment (\> 5 days) with corticosteroids or another immunosuppressive agent~* Active heart (cardiac) disease as defined in the protocol~* Certain scores on an anxiety and depression mood questionnaires

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BKM120 100mg + Fulvestrant (Type: EXPERIMENTAL): BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
- Placebo + Fulvestrant (Type: PLACEBO_COMPARATOR): BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women, aged 18 to 60 years~2. Body mass index 20 kg/m2 to 27 kg/m2~3. Hemoglobin above 130g/L.~4. Normal glucose tolerance in response to a 75g, 2-hr OGTT~Exclusion Criteria:~1. Subject has a history of hepatitis/hepatic disease that has been active within the previous two years.~2. Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr \> 1.5 mg/dL), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP \> 100 or systolic \> 180) or proliferative retinopathy~3. History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.~4. Any history of a MI or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.~5. Any laboratory values: AST \> 2x ULN; ALT \> 2x ULN TSH \> 6 mU/l~6. Current addiction to alcohol or substances of abuse as determined by the investigator.~7. Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation~8. Taking any prescription or non-prescription medications at the time of the study~9. Having donated blood three months prior to and three months post study procedures~10. A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. Those who test positive for pregnancy will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): sitagliptin, 100mg, oral, single dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral, single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Change in Plaque Characteristics With Atorvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute coronary syndrome (myocardial infarction or unstable angina) who will undergo PCI.~* plasma LDL cholesterol levels : \>=100mg/dL and ≤160mg/dL~* at least one atherosclerotic lesion of \>25% stenosis other than culprit lesions of current ACS~Exclusion Criteria:~* Patients who will undergo coronary bypass surgery.~* Patients with major complications during treatment of culprit coronary lesions.~* Patients with an atherosclerotic lesion with \>50% stenosis at a left main trunk.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Atorvastatin 20mg
- 2 (Type: ACTIVE_COMPARATOR): atorvastatin 5mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Male or female patients 18 years of age scheduled to undergo elective colon or colorectal surgery by laparotomy must meet the following criteria:~* Surgery must be scheduled in advance.~* There must be adequate time to complete preoperative bowel preparation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Six Month Plaque and Gingivitis Study Using Colgate Total Toothpaste

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects, ages 18-70, inclusive.~2. Availability for the six-month duration ofthe clinical research study.~3. Good general health.~4. Minimum of 20 uncrowned permanent natural teeth (excluding third molars).~5. Initial gingivitis index of at least 1.0 as determined by the use of the Loe and Silness Gingival Index.~6. Initial plaque index of at least 1.5 as determined by the use of the Quigley and Hein Plaque Index (Turesky Modification).~7. Signed Informed Consent Form.~Exclusion Criteria:~1. Presence of orthodontic bands.~2. Presence of partial removable dentures.~3. Tumor(s) of the soft or hard tissues of the oral cavity.~4. Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone).~5. Five or more carious lesions requiring immediate restorative treatment.~6. Antibiotic use any time during the one month prior to entry into the study.~7. Participation in any other clinical study or test panel within the one month prior to entry into the study.~8. Dental prophylaxis during the past two weeks prior to baseline examinations.~9. History of allergies to oral care/personal care consumer products or their ingredients.~10. On any prescription medicines that might interfere with the study outcome.~11. An existing medical condition which prohibits eating or drinking for periods up to 4 hours.~12. History of alcohol or drug abuse.~13. Pregnant or lactating subjects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Colgate Cavity Protection toothpaste (Type: PLACEBO_COMPARATOR): Brush whole mouth 2x/day with Colgate Cavity Protection toothpaste. This study treatment is currently marketed/sold in Poland
- Colgate Total toothpaste (Type: ACTIVE_COMPARATOR): Brush whole mouth 2x/day with Colgate Total toothpaste . This study treatment is currently marketed/sold in Poland
- Parodontax (Type: ACTIVE_COMPARATOR): Brush whole mouth 2x/day with Parodontax toothpaste. This study treatment is currently marketed/sold in Poland.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed Diagnosis of Hidradenitis Suppurativa by the PI~* Age 18 or older~* Moderate to Severe Hidradenitis Suppurativa as determined by the PI~Exclusion Criteria:~* Inflammatory Bowel Disease~* HIV Positive~* Active Hepatitis B or C Infection~* Pregnant or Breastfeeding~* no concurrent use of any systemic antibiotics/retinoids/imunosuppressants (require washout period of \>5 half lives)~* Any medical, psychological or social condition that, in the opinion of the investigator, would jeopardize the health or well being go the participant during any study procedures or the integrity of the data~* High Suicide Risk as determined by the Columbia Suicide Severity Rating Scale~* History of Keloid Scarring

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Brodalumab 210mg subcutaneously every 2 weeks for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Ascending Dose Study for LCB01-0371

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Health Male between 20 and 45 years of age at the time of screening and a subject with body mass index (BMI) between 19 and 27~2. Medically healthy with no clinically significant screening results through Physical examination, x-ray, 12 lead ECG, Laboratory test~3. Able to donate blood during study period and follow visit.~4. Agree to continue to use a reliable method of birth control until 60 days after study completion.~5. Capable of giving written informed consent and Able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.~Exclusion Criteria:~1. History of liver, kidney, respiratory, musculoskeletal, endocrinologic, neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).~2. History of gastrointestinal problem which is affect to absorption within 6 months from screening~3. History of hypersensitivity or clinically significant adverse drug reaction(s) to the LCB01-0371, same class of the study drugs (linezolid), or other drugs including aspirin and antibiotics.~4. History drug abuse or positive result of urine drug screening test for amphetamine, methamphetamine, barbiturate, cocaine, opiate, benzodiazepine, cannabinoid, methadone, etc.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- LCB01-0371 800mg (Type: EXPERIMENTAL): LCB01-0371 800mg
- LCB01-0371 1200mg (Type: EXPERIMENTAL): LCB01-0371 1200mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent and are willing to comply with protocol requirements~* Are 40 years of age or older.~* Are being evaluated for possible ACS.~* If female, then not of childbearing potential as documented by history or has a negative serum or urine pregnancy test within 4 hours prior to receiving the test drug and agrees to use an acceptable form of birth control.~Exclusion Criteria:~* \<40 years of age.~* Females who are pregnant or lactating.~* History of left ventricular ejection fraction (LVEF)=40%.~* History of MI.~* Acute ST segment elevation on ECG.~* Left bundle branch block on ECG.~* Known history of significant allergy to x-ray contrast media or iodine/iodides.~* Currently or formerly on medication that targets fatty acid uptake or metabolism, eg ranolazine, (Ranexa).~* Administered radiopharmaceutical other than rubidium-82 or thallium-201 within 2 days prior to study enrollment.~* Underwent cardiac stress testing of any kind within 2 days prior to study enrollment.~* Serum creatinine level \>2.0 mg per dL.~* Received investigational compound and/or medical device within 30 days of admission into this study.~* Q-wave abnormalities consistent with previous MI

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iodofiltic Acid I 123 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Systemic Lupus Erythematosus (SLE)~Exclusion Criteria:~* Severe neuropsychiatric or severe renal Systemic Lupus Erythematosus (SLE)~* History of chronic, recurrent, or recent severe infection~* Significant hematologic abnormalities~* History of cancer, heart failure, renal disease, liver disease or other serious illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CDP7657 (Type: EXPERIMENTAL): CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Viagra's Ability to Provide a Better Sexual Experience Through Quality Erections and Satisfaction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male subjects aged 18-65.~* Documented clinical diagnosis of erectile dysfunction confirmed by an IIEF-EF Domain score of less than or equal to 25. (If the subject scores greater than 25 on the IIEF-EF Domain, screening procedures should be terminated.)~Exclusion Criteria:~* Subjects who have been treated with more than 6 doses of sildenafil citrate or any other phosphodiesterase type 5 (PDE-5) inhibitor such as vardenafil or tadalafil for erectile dysfunction \[Note: subjects should not have taken any PDE-5 inhibitors within 4 weeks prior to the date of screening\].

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 18-50 years old (male or female).~* Free from any diabetes related complications (apart from mild background diabetic retinopathy).~* HbA1c \<8.5%.~* Not taking any prescribed medication other than insulin, and treated with a stable insulin regimen composed of a combination of slow/long acting insulin (glargine or detemir) and fast-acting insulin analogues (lispro or aspart), for a minimum of 6 months before the start of the study.~* Demonstrate normal cardiac function in response to exercise.~Exclusion Criteria:~* Aged younger than 18, or older than 50 years.~* Suffering from, or diagnosed with a diabetes related complication (apart from mild background diabetic retinopathy).~* HbA1c \>8.5%.~* Currently taking prescribed medication, and not currently treated with a stable basal bolus regimen composed of a combination glargine or determir, and lispro or aspart for at least 6 months before the start of the study.~* Failure to demonstrate normal cardiopulmonary responses during exercise, or have a medical condition which could prevent completion of exercise or be exacerbated because of.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Basal dose reduction (Type: EXPERIMENTAL): Total daily basal (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk) reduction of 20% versus normal basal dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 30 to 75 at the time of screening visit~* Subjects with type 2 DM diagnosed for at least 3 months before screening~* Subjects with type 2 DM treated with monotherapy of 500mg ≤ metformin ≤ 1000mg for at lest 4 weeks prior to screening~* HbA1c ≥ 7.0% but ≤ 10.0% at the time of screening visit~* 21 kg/m2 ≤ BMI ≤ 40 kg/m2~* A negative pregnancy test for all females of childbearing potential~* Provision of signed and dated informed consent prior to any study procedures~* Ability and willingness to perform SMBG and record the data on the subject's diary~Exclusion Criteria:~* A history of acute metabolic complications such as diabetic ketoacidosis or hyperosmolar nonketotic coma within 3 months before screening~* Current therapy with anti-hyperglycemic agents (except metformin) use in the 4 weeks (8 weeks in case of thiazolidinedione) before screening~* Concomitant treatment prohibited during the study period~  * Any oral hypoglycemic agent other than glimepiride, metformin HCl, and fixed-dose combination of glimepiride and metformin HCl~ * Any insulin therapy over 7 days consecutively or intermittently in order to treat acute metabolic decompensation or systemic infection during the study~ * Intermittent use of systemic corticosteroids or large dose of inhaled steroids~* Subjects with clinically significant renal (serum creatinine level \> 1.5 mg/dL in male and \> 1.4 mg/dL in female) or hepatic disease (ALT and AST \> 2x ULN)~* Clinically significant laboratory abnormality on screening labs or any medical condition that would affect the completion or outcome of the study in the opinion of the investigator and/or sponsor;~* Pregnant or lactating females~* History of drug or alcohol abuse~* Subjects who have a history of noncompliance with regards to follow-up medical care~* Subjects with known hypersensitivity to glimepiride, metformin HCL~* Night-shift workers~* Treatment with any investigational product in the last 3 months before study entry~* Others; subjects who have participated in this study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Amaryl M group
- 2 (Type: ACTIVE_COMPARATOR): Metformin group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete